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ABSTRACT
Objectives: A considerable proportion of endometrial cancer patients are morbidly obese. Management of these cases is 
a serious dilemma. The aim of this study was to investigate the relevance of laparoscopic route and omission of lymphad-
enectomy as morbidity-reducing strategies in this special population. 
Material and methods: Endometrial cancer patients’ archival records were retrospectively reviewed and cases with body 
mass index ≥ 40 kg/m2 were selected. A comparative evaluation of their characteristics and survival rates were performed. 
Firstly, according to the surgical approach; laparoscopy or laparotomy, and then regarding to performing lymphadenec-
tomy or not.
Results: There were 146 patients enrolled in this study. Whereas, significantly higher postoperative complications and 
longer hospital stays were determined in the laparotomy compared to laparoscopy groups. Five years disease-free and 
overall survival were not significantly different (83.6% vs 70.7%, p = 0.184 and 83.9% vs 86.6%, p = 0.571, respectively). On 
the other hand, operation length, postoperative hospitalization time, both intraoperative and postoperative complications 
were significantly lower in the non-lymphadenectomy compared to the lymphadenectomy groups. However, five-years 
disease-free and overall survival were not significantly different (77.3% vs 81.3%, p = 0.586 and 87.5% vs 78%, p = 0.479, 
respectively).
Conclusions: Laparoscopic approach and omission of lymphadenectomy are worthy policies in the morbidly obese en-
dometrial cancer patients. 
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INTRODUCTION
Obesity and particularly morbid obesity is a widening is-
sue around the world. The World Health Organization (WHO) 
had identified morbid obesity as patients with body mass in-
dex more than 40 kg/m2 [1]. The robust association between 
obesity and endometrial cancer risk has been emphasized 
in many studies [2–4]. It was reported that morbidly obese 
patients have nine times increased risk for endometrial 
cancer comparing to the normal-weight population [3]. Fur-
thermore, 19% to 36% of the endometrial cancer’ patients 
were reported to be morbidly obese [5]. Inadequate activity 
and obesity-linked medical comorbidities in the morbidly 
obese endometrial cancer patients were supposed to have 
contributed in their management complexity [5]. Actually, 
not just the surgery of the morbidly obese endometrial 
cancer cases, but dealing with all of their health procedures 
including examination, evaluation with imaging methods, 
per-operative and postoperative morbidity and complica-
tions, is a serious predicament. 
Surgery representing in total hysterectomy and bilateral 
salpingo-oophorectomy (TH-BSO) with or without lymphad-
enectomy ± omentectomy is the cornerstone of the endo-
metrial cancer treatment [6]. Surgery can be performed via 
laparotomy, robotic assisted or conventional laparoscopy. 
Since minimal invasive surgery has been proven effective in 
improving the perioperative and postoperative outcomes 
without compromising survival, it was incorporated in the 
surgical management of endometrial cancer throughout 
the last two decades [7]. Besides, laparoscopic surgery had 
been validated for the long-term outcomes of low risk as 
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well as high-risk endometrial cancer cases in many studies 
[8]. However, morbidly obese patients are a colossal obstacle 
for all surgical approaches. 
While a lymphadenectomy is beneficial for more precise 
adjuvant treatment triage by obtaining thorough stage 
designation and prognosis prediction of the EC patients, 
there is no consensus regarding its therapeutic benefit [9]. 
In addition, extent (pelvic or pelvic-paraaortic — until the 
inferior mesenteric artery or up to the left renal vein), man-
ner and technique (full dissection or sampling, based on 
frozen section or sentinel node) of the lymphadenectomy 
are controversial, also [9, 10]. Hitherto, therapeutic impact 
of the lymphadenectomy in the EC was shown only by retro-
spective studies and was not confirmed by the randomized 
prospective studies [9–11]. 
Medically, morbidly obese EC patients are a high risk 
special population along all their treatment phases. There-
fore, morbidity-reducing strategies are essential in these cas-
es. However, such strategies should not harm the long-term 
oncological outcomes of these patients. In this study we 
investigated whether choosing the laparoscopic route and 
omission of the lymphadenectomy are or not appropriate 
policies in the morbidly obese EC patients. 
MATERIAL AND METHODS
The archival records and pathological reports of the 
endometrial cancer cases, who were operated and followed 
up in Çukurova University Gynecologic Oncology Center be-
tween January 2008 and December 2018, were reviewed, ret-
rospectively. Patients with body mass index ≥ 40 kg/m2 were 
selected for this study. Body mass index [weight (kg)/height 
(m2)] was calculated and classified according to the WHO 
guidelines. Demographic, clinical, surgical, pathological and 
follow-up data concerning to these patients were obtained. 
Comparative evaluations of the patients’ characteristics and 
survival rates were performed, firstly according to the surgi-
cal approach; laparoscopy or laparotomy, and then whether 
or not to perform a lymphadenectomy. Compared variables 
included age, body mass index (BMI), comorbidities, surgical 
approach, surgical procedure, operation time, periopera-
tive and postoperative complications, hospitalization time, 
histological type, stage, grade, myometrial invasion (MI), 
retroperitoneal lymph node involvement, lymphovascular 
invasion (LVSI), adjuvant treatments and follow-up data. 
A routinely informed consent was taken from all partici-
pants. An approval for this study was obtained from the 
local committee. 
In general, surgery was performed laparoscopically or 
by laparotomy based on the patient’s choice. The main 
surgical procedures were total hysterectomy-bilateral sal-
pingo-oophorectomy with or without pelvic and para-aortic 
lymphadenectomy. While, all cases underwent TH-BSO, the 
decision of performing a lymphadenectomy and its extent 
(pelvic or pelvic and paraaortic) was taken upon the case’s 
medical performance, the surgical facility and intraoperative 
frozen section result. The frozen section was performed in all 
cases and it was the main router for the lymphadenectomy 
decision. Hence, a lymphadenectomy was not considered 
for patients with, stage 1a, FIGO grade 1–2, < 2 cm endome-
trioid tumors (low-risk factors). In the presence of any of the 
following circumstances: endometrioid adenocarcinoma 
grade 3, tumor diameter > 2 cm, ≥ 50% myometrial invasion, 
stage > 1a or non-endometrioid histologies, a lymphadenec-
tomy was performed in medically and surgically eligible 
cases. In the case of FIGO grade 1–2 endometrioid adeno-
carcinoma with < 50% MI and > 2 cm tumor, only a pelvic 
lymphadenectomy was carried out. An omentectomy was 
administered to patients with non-endometrioid histology 
and in case of omental involvement. Pelvic lymphadenec-
tomy was defined as removing bilaterally the lymph nodes 
located from the circumflex iliac vein to the iliac bifurcation 
along the external iliac vessels, the nodes along the inter-
nal iliac vessels, and within the interiliac distance and the 
obturator fossa. In addition to the lymph nodes described 
above as pelvic lymphadenectomy, resection of the lymph 
nodes located from the bifurcations of the common iliac 
vessels up to the left renal vein including; presacral, caval, 
aortocaval, periaortic, left paraaortic (below and above the 
inferior mesenteric artery), and right paracaval fields, was 
identified as pelvic and paraaortic lymphadenectomy. 
All specimens were assessed by expert gynecologic 
pathologists. Comorbidities were accepted as any con-
comitant chronic disease. International Federation of Gy-
necology and Obstetrics FIGO 2009 staging guideline for 
endometrial cancer was utilized. Stages of cases operated 
before 2009 were rearranged accordingly. Grade was also 
identified according to 1988 FIGO grading system. Adju-
vant therapies (brachytherapy, external beam radiother-
apy and/or chemotherapy) were considered for patients 
with ≥ intermediate risk factors. The period between date 
of the histopathologic diagnosis and recurrence was identi-
fied as disease-free survival. Overall survival was defined as 
time between date of histopathologic diagnosis and date 
of death from any cause.
Data were analyzed using SPSS software version 
23.0 (IBM, Armonk, NY, USA). Descriptive analyses were 
presented as mean ± standard deviation, number and per-
centage. Normally distributed continuous variables were 
analyzed using student t-test. Categorical data were ana-
lyzed using Chi- square test or Fisher’s exact test. Survival 
analysis were realized with Kaplan–Meier method and the 
differences in the survival curves were calculated through 
the log-rank test. P value was considered significant at the 
level < 0.05.
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RESULTS
During the study period, 146 patients were determined 
to be eligible for recruitment to this study. Two different 
comparisons were performed to the study population: 
Firstly, according to the surgical route and then in regard 
to applying a lymphadenectomy or not. There were 65 cas-
es in the laparotomy (LT) and 81 in the laparoscopy (LS) 
groups. Comparison between patients concerning their sur-
gical approach is summarized in Table 1. Patients’ mean age 
was 58.94 ± 11.4 and 58.18 ± 8.9 in the LT and LS groups, 
respectively (p = 0.652). The average BMI of the LT group 
(44.37 ± 4.8) was significantly lower comparing to the LS 
group (46.13 ± 5.3) (p = 0.042). Significant proportion of 
both groups had comorbidities, 60.3% of the LT and 67.9% 
of the LS group (p = 0.345). While, a lymphadenectomy 
was performed in 26 (40%) (pelvic and paraaortic: 18, only 
pelvic: 8) cases of the LT group, it was only carried out in 
14 (17.3%) (pelvic and paraaortic: 8, only pelvic: 6) cases of 
the LS group (p = 0.007). There were no significant differ-
ences between groups with respect to the operation time 
(LT: 96.0 ± 32.6, LS: 89.5 ± 41.1, p = 0.303). Whereas, no sig-
nificant differences between LT and LS groups were noted 
regarding to the intraoperative complications (p = 0.915), 
there were significantly higher postoperative complica-
tions in the LT group comparing to the LS group (15.9% 
vs 1.2%, respectively, p = 0.002). Wound infection was the 
most encountered postoperative complication among the 
LT patients. The mean of postoperative hospital stay was 
significantly longer in the LT group (5.42 ± 3.3) comparing 
to the LS group (3.07 ± 1.0) (p < 0.001). Most of the patients 
Table 1. Comparison between patients concerning to their surgical approach
Variables (mean ± SD) Laparotomy Laparoscopy p
Age [years] 58.94 ± 11.4 58.18 ± 8.9 0.652
Body Mass Index [kg/m2] 44.37 ± 4.8 46.13 ± 5.3 0.042
Operation time [minute] 96.0 ± 32.6 89.5 ± 41.1 0.303
Postoperative hospitalization time [day] 5.42 ± 3.3 3.07 ± 1.0 < 0.001
N (%) N (%)
Comorbidities 
No 25 (39.7) 26 (32.1) 0.345
Yes 38 (60.3) 55 (67.9)
Intraoperative
complications
No 63 (97.0) 78 (96.3) 0.915
Yes 2 (3.0) 2 (3.7)
Postoperative
complications
No 53 (84,1) 80 (98.8) 0.002
Yes 10 (15.9) 1 (1.2)
LND
No 39 (60.0) 67 (82.7) 0.007
Pelvic 8 (12.3) 6 (7.4)
Pelvic + Paraaortic 18 (27.7) 8 (9.9)
Histopathology
Endometrioid 50 (76.9) 69 (85.2) 0.201
Non-endometrioid 15 (23.1) 12 (14.8)
Grade 
1 27 (48.2) 52 (65.8) 0.118
2 25 (44.6) 24 (30.4)
3 4 (7.1) 3 (3.8)
Stage 
Uterus confined (stage 1–2) 51 (78.5) 76 (93.8) 0.006
Extrauterine spread (stage 3–4) 14 (21.5) 5 (6.2)
MI
< 50 39 (60.9) 52 (70.3) 0.249
≥ 50 25 (39.1) 22 (29.7) 
LVSI
No 33 (51.6) 61 (76.3) 0.004
Yes 31 (48.4) 19 (23.8)
LN involvement
Negative 56 (88.9) 68 (98.6) 0.020
Positive 7 (11.1) 1 (1.4)
Adjuvant treatments
No 31 (48.4) 57 (71.3) 0.005
Yes 33 (51.6) 23 (28.8)
LT — laparotomy; LS — laparoscopy; SD — Standard deviation; LND — lymph node dissection; MI — myometrial invasion; LVSI — lymphovascular space invasion
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in both groups had endometrioid histology (76.9% of the 
LT and 85.2% of the LS, p = 0.201). Grade distribution was 
similar between groups (p = 0.118). Rate of advanced stage 
(3–4) disease was 21.5% and 6.2% in the LT and LS groups, 
respectively (p = 0.006). MI was ≥ 1/2 in 25 (39.1%) and 
22 (29.7%) cases in the LT and LS groups respectively, with-
out significant differences (p = 0.249). LVSI was observed in 
48.4% of the LT group and 23.8% of the LS group (p = 0.004). 
Lymph node (LN) was involved in 7 (11.1%) cases of the LT 
group and 1 case (1.4%) of the LS group (p = 0.020). Adjuvant 
treatments were administered to 33 (51.6%) and 23 (28.8%) 
patients of the LT and LS groups, respectively (p = 0.005).
Comparison between patients with respect to adding 
lymphadenectomy or not to the surgical procedure is sum-
marized in Table 2. The mean age of the non-lymphadenec-
tomy and lymphadenectomy groups were 57.88 ± 10.4 and 
60.26 ± 8.8, respectively without significant differences 
(p = 0.210). Comorbidity rates were also identical between 
the groups (62.5% vs 70% respectively, p = 0.399). The aver-
age BMI was 45.87 ± 5.3 in the non-lymphadenectomy group 
and 43.96 ± 4.5 in the lymphadenectomy group (p = 0.034). 
While, laparotomy was the surgical method of 36.8% and 
65% of the non-lymphadenectomy and lymphadenectomy 
groups, respectively, laparoscopy was the surgical route 
for the rest cases (p = 0.002). The mean operation time was 
significantly lower in the non-lymphadenectomy group 
compared to the lymphadenectomy group (79.9 ± 27.3 vs 
125.1 ± 41.3, respectively, p < 0.001). Both intraoperative 
(2.8% vs 5%, p = 0.040) and postoperative (2.8% vs 21%, 
p = 0.001) complications were significantly lower in the 
non-lymphadenectomy group compared with the lymph-
adenectomy group. The average of postoperative hospital-
ization time was also significantly lower in the non-lymph-
adenectomy group compared to the lymphadenectomy 
Table 2. Comparison between patients according to lymphadenectomy
Variables (mean ± SD) No lymphadenectomy Lymphadenectomy p
Age [years] 57.88 ± 10.4 60.26 ± 8.8 0.210
Body Mass Index [kg/m2] 45.87 ± 5.3 43.96 ± 4.5 0.034
Operation time [minute] 79.9 ± 27.3 125.1 ± 41.3 < 0.001
Postoperative hospitalization time [day] 3.37 ± 1.1 6.1 ± 4.0 < 0.001
N (%) N (%)
Comorbidities 
No 39 (37.5) 12 (30.0) 0.399
Yes 65 (62.5) 28 (70.0)
Treatment 
Laparotomy 39 (36.8) 26 (65.0) 0.002
Laparoscopy 67 (63.2) 14 (35.0)
Intraoperative
complications
No 103 (97.2) 38 (95.0) 0.040
Yes 3 (2.8) 2 (5.0)
Postoperative
complications
No 103 (97.2) 30 (79.0) 0.001
Yes 3 (2.8) 8 (21.0)
Histopathology
Endometrioid 88 (83.0) 31 (77.5) 0.444
Non-endometrioid 18 (17.0) 9 (22.5)
Grade 
1 66 (65.3) 13 (38.2) 0.018
2 30 (29.7) 19 (55.9)
3 5 (5.0) 2 (5.9)
Stage 
Uterus confined (stage 1–2) 97 (91.5) 30 (75.0) 0.008
Extrauterine spread (stage 3–4) 9 (8.5) 10 (25.0)
MI
< 50 72 (72.0) 19 (50.0) 0.015
≥ 50 28 (28.0) 19 (50.0) 
LVSI
No 76 (73.1) 18 (45.0) 0.001





No 73 (70.2) 15 (37.5) < 0.001
Yes 31 (29.8) 25 (62.5)
SD — Standard deviation; MI — myometrial invasion; LVSI — lymphovascular space invasion; LN — lymph node
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group (3.37 ± 1.1 vs 6.1 ± 4.0, respectively, p < 0.001). En-
dometrioid type endometrial cancer consisted 83% of the 
non-lymphadenectomy patients and 77.5% of the lymph-
adenectomy group. With respect to the histopathological 
type, no significant differences were determined between 
groups (p = 0.444). Whereas, the majority of cases in the 
non-lymphadenectomy group was grade 1 (65.3%) and 
significant proportion of the lymphadenectomy group was 
grade 2 (55.9%), both groups had similar rates of grade 
3 cases (5% and 5.9%, respectively). Most of the cases in both 
groups were confined to the uterus, only 8.5% and 25% of 
the non-lymphadenectomy and lymphadenectomy groups, 
respectively, were determined to have extrauterine disease 
(p = 0.008). Myometrium was invaded ≥ 1/2 in 28% and 
50% of the non-lymphadenectomy and lymphadenectomy 
groups, respectively (p = 0.015). The ratio of lymphovascular 
invasion was 26.9% in the patients who did not undergo 
a lymphadenectomy and 55% in patients who underwent 
lymphadenectomy (p = 0.001). Among patients who under-
went a lymphadenectomy, seven (17.9%) cases harbored 
positive LNs. Adjuvant treatments were applied in 31 (29.8%) 
and 25 (62.5%) patients of the non-lymphadenectomy and 
lymphadenectomy group, respectively (p < 0.001).
The mean of the follow-up period was 51 months. 
Five-years disease-free survival (DFS) and overall survival 
(OS) rates of the LT and LS groups were 83.6% vs 70.7% 
(p = 0.184), and 83.9% vs 86.6% (p = 0.571), respectively (Fig. 1). 
Five-year DFS and OS rates of the non-lymphadenecto-
my and lymphadenectomy groups were 77.3% vs 81.3% 
(p = 0.586), and 87.5% vs 78% (p = 0.479), respectively (Fig. 2). 
A multivariate analysis was performed, and only age (HR: 
1.105, 1.034–1.182) with histology (HR: 3.262, 1.017–10.463) 
for DFS and stage (HR: 7.182, 1.310–39.393) for OS were 
determined as independent prognostic factors (Tab. 3).  
DISCUSSION
The morbidly obese patients are known for their high 
risk for endometrial cancer. However, endometrial cancer 
tends to have low grade, early stage, endometrioid type 
and good prognosis, in this special population [2, 3, 12]. 
Nevertheless, treatment of these patients encompasses high 
risk of many morbidities such as; hemodynamic instabil-
ity, tension pneumothorax, wound infection, healing, and 
thrombosis [13]. Hence, operating, postoperative manage-
ment and dealing with possible complications of these cases 
are serious dilemmas. Furthermore, the increased healthcare 
Figure 1. DFS and OS of the LS and LT groups
Figure 2. DFS and OS of the lymphadenectomy and non-lymphadenectomy groups
458
Ginekologia Polska 2020, vol. 91, no. 8
www. journals.viamedica.pl/ginekologia_polska
utilization in these cases leads to high costs. Therefore, opti-
mal treatment to minimize the morbidity of these patients 
is essential. Herein, two morbidity-reducing strategies for 
this population (laparoscopic surgery and omitting lymph-
adenectomy) were suggested and tested in this study. No 
significant difference was observed in term of both DFS and 
OS between LT and LS groups, in the current study. Similarly, 
both of DFS and OS did not significantly differ whether 
lymphadenectomy was performed or not.
Laparoscopic surgery is recommended as –level of evi-
dence: I, strength of recommendation: A- for the manage-
ment of low and intermediate risk endometrial cancer ac-
cording to the European guidelines [14]. In addition, several 
studies have demonstrated the efficacy and oncological 
safety of laparoscopy in the high-risk endometrial cancer 
[8, 15]. Nevertheless, there are no randomized prospective 
trials nor sufficient researches on the oncological safety of 
the surgical approach for endometrial cancer that exclu-
sively concentrates on the morbidly obese patients [16, 17]. 
Lower blood loss, less pain, lower postoperative complica-
tions, shorter hospital stay and recovery, and less cost are 
well-known advantages of laparoscopic surgery comparing 
to the laparotomy [6]. Cheng et al. [16] postoperative com-
plications, length of hospital stay, blood loss and need of 
transfusion were significantly lower in the morbidly obese 
endometrial cancer patients who were treated with LS com-
paring to those with open surgery. Mendivil and colleagues, 
[13] also reported a shorter postoperative hospitalization 
period and less blood loss with minimally invasive surgery 
(MIS) relative to the open surgery in the morbidly obese en-
dometrial cancer cases. Similarly, comparing to laparotomy 
MIS was linked to less intraoperative and postoperative 
complications including: blood transfusions, mechanical 
ventilation, urinary and gastrointestinal injuries, wound 
infection, thromboembolism, and lymphedema for the mor-
bidly obese endometrial cancer population in a comparative 
analysis by Chan et al. [18] Compatible with these results, 
LS was associated with significantly lower postoperative 
complications and shorter postoperative hospitalization 
time in the current study. Beside the advantages of the 
short-term surgical results, long-term oncologic outcomes 
were shown to be comparable between the LS and LT arms, 
in the present study. 
The lymphadenectomy in endometrial cancer is ben-
eficial for accurate staging, prognosis prediction and more 
precise adjuvant treatments selection [10]. However, its 
therapeutic utility remains controversial since it has never 
been proven by the prospective studies [9, 10]. Furthermore, 
a benefit of the lymphadenectomy in term of disease-free 
survival (HR: 1.23, 95% GA: 0.96–1.58) or overall survival 
(HR: 1.07, 95% GA: 0.81–1.43) was not reported in the last 
2017 updated Cochrane review on the role of lymphadenec-
tomy in endometrial cancer [9]. On the other hand, surgery 
related systemic morbidity (RR: 3.72, 95% GA: 1.04–13.27) 
and formation of lymphocyst/lymphedema (RR: 8.39, 95% 
GA: 4.06–17.33) were clearly increased in the lymphadenec-
tomy patients comparing to the non-lymphadenectomy 
[9]. Even a lymphadenectomy in the morbidly obese endo-
metrial cancer is an applicable procedure in high-volume 
qualified centers; it still harbors (particularly para-aortic part) 
serious surgical difficulties and morbidities [3, 17]. There-
fore, simply we argued that if there is no survival benefit 
of lymphadenectomy procedures in this risky population, 
it is reasonable to neglect lymphadenectomies in these 
patients. In our study, patients who underwent a lymphad-
enectomy were compared with those who did not, and no 
significant difference was obtained between groups in terms 
of both DFS and OS. However, it should be noted that the 
insufficient number of intermediate/high risk or type two 
cases in our study had restricted us to perform a sub-analysis 
concerning these patients. 
Through this investigation, laparoscopic surgery and 
omitting lymphadenectomy in the morbidly obese endome-
trial cancer were found effective as morbidity-reducing strat-
egies without harming the survival outcome. In addition, 
remarkable reduction in the total cost could be achieved 
with these strategies, due to the decreased procedures and 
morbidities. However, this argument needs to be supported 
by a cost-effectiveness analysis, which was not performed 
in the current study. Withal, the retrospective nature and its 
potential biases were the main weaknesses of our study. On 
the contrary, restricting the study population to morbidly 
obese women (BMI of 40 kg/m2 or more), operating and 
evaluation of all cases by the same team of gynecological 
oncologists and gynecological pathologists from single 




Age 1.105 (1.034–1.182) 1.045 (0.966–1.131)
Comorbidities 0.832 (0.306–2.258) 3.585 (0.524–24.513)
Surgical route 1.686 (0.692–4.111) 1.289 (0.326–5.102)
Stage 0.631 (0.070–5.726) 7.182 (1.310–39.393)
Grade 1.616 (0.681–3.837) 1.534 (0.497–4.735)
Histology 3.262 (1.017–10.463) 1.843 (0.416–8.156)
MI 1.889 (0.296–12.079) 1.607 (0.195–13.256)
LVSI 0.298 (0.080–1.103) 0.191 (0.030–1.202)
 LN involvement 8.285 (0.704–97.467) 1.143 (0.400–3.262)
Adjuvant treatments 1.115 (0.175–7.097) 2.655 (0.309–22.792)
DFS — disease-free survival; OS — overall survival; HR — hazard ratio; CI 
— confidence interval; MI — myometrial invasion;  LVS — lymphovascular 
space invasion; LN — lymph node dissection
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academic center, and the long follow-up period were the 
main strengths.
In conclusion, parallel to our study results, laparoscopy 
should be preferred, and lymphadenectomy could be omit-
ted in the morbidly obese endometrial cancer patients.
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